StockNews.AI
INTS
StockNews.AI
15 days

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

1. Intensity Therapeutics extended cash runway into 2026 via share sale. 2. Average sale price per share exceeded June 2025 offering by over 10%.

2m saved
Insight
Article

FAQ

Why Bullish?

Extending cash runway suggests operational stability. Historical examples show enhanced stock performance following successful capital raises.

How important is it?

The extension of the cash runway and the higher average share price reflect strong financial health, likely reassuring investors.

Why Short Term?

Recent funding provides immediate stability but longer-term impact depends on clinical developments.

Related Companies

BMYMRKAMGN
•     Cash runway extended into the second half of 2026 •     Average sales price per share was over 10% higher than the June 2025 public offering price SHELTON, Conn. , Aug. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces that in July 2025 the Company added $6.6 million in gross proceeds ($6.3 million net) by selling 19,868,658 shares of its common stock via its At-the-Market offering (the "ATM") at an average price of $0.3323 per share.

Related News